430306004: Certolizumab pegol (substance)

SNOMED CT Concept\Substance\...

\Substance categorized by disposition\Immunomodulator\Tumor necrosis factor alpha inhibitor\Certolizumab pegol (substance)

\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Tumor necrosis factor alpha inhibitor\Certolizumab pegol (substance)
\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Gastrointestinal agent (substance)\Certolizumab pegol (substance)
\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Monoclonal antibody\Certolizumab pegol (substance)

\Substance categorised by structure\Chemical\Chemical categorized by structure (substance)\...

\Nitrogen and/or nitrogen compound (substance)\Nitrogen compound\Organic nitrogen compound\Amide and/or amide derivative (substance)\Substituted amide (substance)\Polypeptide\Protein\Antibody\Monoclonal antibody\Certolizumab pegol (substance)

\Organic compound\Organic nitrogen compound\Amide and/or amide derivative (substance)\Substituted amide (substance)\Polypeptide\Protein\Antibody\Monoclonal antibody\Certolizumab pegol (substance)

\Biological substance\Protein and/or protein derivative\Protein\Antibody\Monoclonal antibody\Certolizumab pegol (substance)
\Biological substance\Immunologic substance\Antibody\Monoclonal antibody\Certolizumab pegol (substance)
\Biological substance\Polypeptide\Protein\Antibody\Monoclonal antibody\Certolizumab pegol (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2008. Module: SNOMED CT core

Descriptions:

Expanded Value Set

Outbound Relationships	Type	Target	Active	Characteristic	Refinability	Group	Values
Certolizumab pegol (substance)	Is a	agent contre une maladie inflammatoire de l'intestin	false	Inferred relationship	Some
Certolizumab pegol (substance)	Is a	agent d'anticorps monoclonal	false	Inferred relationship	Some
Certolizumab pegol (substance)	Is a	Monoclonal antibody	true	Inferred relationship	Some
Certolizumab pegol (substance)	Is a	Gastrointestinal agent (substance)	true	Inferred relationship	Some
Certolizumab pegol (substance)	This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context.	Tumor necrosis factor alpha inhibitor (disposition)	true	Inferred relationship	Some
Certolizumab pegol (substance)	Is a	Tumor necrosis factor alpha inhibitor	true	Inferred relationship	Some

Inbound Relationships	Type	Active	Source	Characteristic	Refinability	Group
Product containing certolizumab pegol (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Certolizumab pegol (substance)	Inferred relationship	Some	1
Certolizumab pegol 200mg powder for injection solution vial + diluent	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Certolizumab pegol (substance)	Inferred relationship	Some
Certolizumab pegol therapy (procedure)	Direct substance	True	Certolizumab pegol (substance)	Inferred relationship	Some	2
Product containing precisely certolizumab pegol 200 milligram/1 vial powder for conventional release solution for injection (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Certolizumab pegol (substance)	Inferred relationship	Some
Product containing only certolizumab pegol (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Certolizumab pegol (substance)	Inferred relationship	Some	1
Product containing precisely certolizumab pegol 200 milligram/1 vial powder for conventional release solution for injection (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Certolizumab pegol (substance)	Inferred relationship	Some	1
Product containing precisely certolizumab pegol 200 milligram/1 vial powder for conventional release solution for injection (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Certolizumab pegol (substance)	Inferred relationship	Some	1
Product containing certolizumab pegol in parenteral dose form (medicinal product form)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Certolizumab pegol (substance)	Inferred relationship	Some	1
Certolizumab pegol only product in parenteral dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Certolizumab pegol (substance)	Inferred relationship	Some	1
Product containing precisely certolizumab pegol 200 milligram/1 milliliter conventional release solution for injection (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Certolizumab pegol (substance)	Inferred relationship	Some	1
Product containing precisely certolizumab pegol 200 milligram/1 milliliter conventional release solution for injection (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Certolizumab pegol (substance)	Inferred relationship	Some	1

Reference Sets

GB English

US English

Back to Start

Id	Description	Lang	Type	Status	Case?	Module
2708529014	Certolizumab pegol (substance)	en	Fully specified name	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
2764885014	Certolizumab pegol	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
372131000195115	certolizumab pegolo	it	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module
367461000077114	certolizumab pegol	fr	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module
799481000172116	certolizumab pégol	fr	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module
654431000274114	Certolizumab Pegol	de	Synonym (core metadata concept)	Active	Entire term case sensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module